StemCyte International, Ltd. (TPE:4178)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
18.60
-0.30 (-1.59%)
At close: Jun 2, 2026
Market Cap4.02B -23.5%
Revenue (ttm)357.74M -8.5%
Net Income-179.45M
EPS-0.93
Shares Out 215.87M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume373,667
Open18.95
Previous Close18.90
Day's Range18.55 - 18.95
52-Week Range18.00 - 34.10
Betan/a
Analystsn/a
Price Targetn/a
Earnings DateAug 14, 2026

About StemCyte International

StemCyte International, Ltd., a biotechnology company, develops cord blood–based cell therapies in the United States and Taiwan. The company engages in the research and development of biotechnology and cell-based new drugs; supply of cellular materials; and operation of cord blood cell banks. It also offers umbilical cord blood transplantation services; and cell products and services. In addition, the company provides REGENECYTE, an allogeneic umbilical cord blood cellular biotherapy for the treatment of cancer, hematological disorders, immune-... [Read more]

Industry Miscellaneous Health And Allied Services, Not Elsewhere Classified
Founded 1997
Country Cayman Islands
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 4178
Full Company Profile

Financial Performance

In 2025, StemCyte International's revenue was 368.91 million, a decrease of -3.60% compared to the previous year's 382.69 million. Losses were -176.81 million, -14.03% less than in 2024.

Financial Statements